Gut microbiota modulation through Traditional Chinese Medicine (TCM) - improving outcomes in Gastrointestinal (GI) cancer prevention and management

癌症预防 医学 中医药 肠道菌群 胃肠道癌 癌症 传统医学 内科学 替代医学 重症监护医学 结直肠癌 病理 免疫学
作者
Yuying Wang,Yu Zeng,Xiaoli Chen,Aiping Lu,Wei Jia,Kenneth Cheung
出处
期刊:Pharmacological research [Elsevier BV]
卷期号:13: 100528-100528 被引量:6
标识
DOI:10.1016/j.prmcm.2024.100528
摘要

Introduction: Gastrointestinal (GI) cancers, such as colorectal cancer, pancreatic cancer and gastric malignancies, are increasing in prevalence and are notorious for poor prognosis and lack of satisfactory curative therapies. Emerging evidence indicates that the trillions of gut microbiotas in the GI tract play a crucial role in maintaining health and preventing disease, making it a promising target in GI cancer management. Additionally, the longstanding tradition and wisdom of Traditional Chinese medicine (TCM) are appreciated for offering valuable insights to complement current therapies against GI cancers. According to TCM principles, GI disorders are primarily attributed to ‘Qi-deficiency’ and disharmony among organs functions and Yin-yang imbalance. Treatment strategies not only include herbal formulations but also encompass non-pharmacological methods. For instance, well-known remedies such as Gegan Qing Lian Decoctions and Aidi injection have a long-standing history of treating GI disorders. These herbal combinations are considered Qi tonics which address the root causes of GI cancer. Furthermore, Reishi Mushroom and Ginseng are for their immune-supportive properties and ability to enhance overall vitality. Turmeric and Chinese rhubarb are noted for their anti-inflammatory, detoxifying and blood-nourishing effects. TCM also incorporates non-pharmacological interventions such as acupuncture and moxibustion, which may yield synergistic effects. The therapeutic benefits of these approaches, coupled with their symptom-relieving abilities, have provided insights for the potential integration with conventional treatments such as immunotherapy and chemotherapy. Several clinical trials have demonstrated positive outcomes, highlighting the involvement of gut microbiota in mediating the effects of these herbal interventions within the GI environment. Methods: A comprehensive literature search was conducted using keywords including Traditional Chinese medicines (TCMs), Gastrointestinal (GI) cancers, gut microbiota, dysbiosis, GI disorders. Initially, a total of 300 articles published up to 2024 were identified, of which 180 articles were selected for inclusion in this review based on their relevance to TCM interventions and the modulation of gut microbiota in relation to GI cancer, either directly or indirectly. A variety of study designs including meta-analyses, systematic reviews, randomized controlled trials, and studies conducted on both human and rats are included. Results: This review highlights the functions of gut microbiota and the implications of microbial dysbiosis in GI carcinogenesis, specifically focusing on the mechanisms that link disruptions in gut microbial communities to cancer progression. Additionally, it highlights the potential integration of Traditional Chinese Medicine into conventional cancer treatment and management by both pharmacological and non-pharmacological approaches. Discussion: The review discusses the potential of TCM-based interventions to modulate the microbiome and mitigate GI cancer, along with the mechanisms through which TCM interacts with gut microbiota. Furthermore, it highlights the necessity for innovative microbiome-based approaches in GI cancer management. In conclusion, there is a critical need for more effective microbiome-based strategies that incorporate TCM, highlighting the future direction of clinical trials aimed at exploring more possibilities of involving TCM to GI cancer treatments. While conventional treatments such as chemotherapy and immunotherapy remain important, the integration of TCM may serve as complementary strategies in GI therapy. To advance the understanding of TCM-microbiome interactions, high-quality, placebo-controlled, randomized, double-blind clinical trials should be conducted.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
苹果安阳发布了新的文献求助10
刚刚
彭于晏的应助被懒鱼采纳,获得10
刚刚
lli完成签到,获得积分10
1秒前
柔弱嵩完成签到,获得积分10
1秒前
sfjlyz发布了新的文献求助10
1秒前
可了不得完成签到 ,获得积分10
1秒前
sfjlyz发布了新的文献求助10
1秒前
chengzi完成签到,获得积分10
1秒前
嘻嘻完成签到,获得积分10
2秒前
DSL发布了新的文献求助10
2秒前
,,发布了新的文献求助10
2秒前
充电宝的应助被siriuslee99采纳,获得10
2秒前
万能图书馆的应助被zz采纳,获得10
2秒前
2秒前
3秒前
丘比特的应助被从容的帽子采纳,获得10
3秒前
3秒前
3秒前
CharlieYue发布了新的文献求助10
4秒前
镜霖发布了新的文献求助10
4秒前
丸giao完成签到 ,获得积分10
4秒前
Ohh发布了新的文献求助20
5秒前
万能图书馆的应助被DiaoZihao采纳,获得10
5秒前
5秒前
xyy完成签到,获得积分10
6秒前
俞静怡发布了新的文献求助10
6秒前
wumin26完成签到,获得积分10
6秒前
wang完成签到,获得积分10
7秒前
7秒前
范范发布了新的文献求助10
8秒前
Henry完成签到,获得积分10
8秒前
Frain完成签到,获得积分10
8秒前
8秒前
WQQ完成签到,获得积分10
9秒前
Jing发布了新的文献求助10
9秒前
LIFE完成签到,获得积分20
9秒前
9秒前
awwwww完成签到,获得积分10
9秒前
10秒前
TIANJINGRUN发布了新的文献求助10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology)求助 1000
Encyclopedia of Modern Artificial Intelligence 1000
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8153299
求助须知:如何正确求助?哪些是违规求助? 9549963
关于积分的说明 21695977
捐赠科研通 7741796
什么是DOI,文献DOI怎么找? 3425434
关于科研通互助平台的介绍 2550601
邀请新用户注册赠送积分活动 2469116